B2i Digital

🌍 From core operations to new initiatives, Heidmar’s roadmap shows how the company is building sustainable momentum.   💬 CEO Pankaj Khanna discusses how strategic acquisitions, new market entries, and expanded capabilities are setting the stage for long-term value creation. ⚙️ Find out how this one-stop maritime solutions provider is positioning for what’s next. ⚓ Heidmar Inc. Q2 2025: Strengthening Core Operations and Launching New Initiatives. 💡 📽️ Watch discussion here: https://lnkd.in/dkxHD2YE #shipping #maritime #ceo #shipmanagement #pooloperator

Applied Energetics, Inc. (OTCQB: AERG), a leader in ultrashort pulse laser technology and advanced directed energy solutions, achieved a major milestone today with the first live multi-drone camera kills using its prototype Pulsed Laser Air Defense (PLAID™) gimbal. Applied Energetics is a B2i Digital Featured Company. View its profile at https://lnkd.in/eVEkcBCH. BIG DAY today in the Applied Energetics Battle Lab! The team successfully demonstrated first multi-drone camera kills — four drones, four disabled cameras in just four seconds — using our early prototype Pulsed Laser Air Defense (PLAID™) gimbal. What you’re seeing in this demonstration: - Objects 2, 3, and 4 were FPV drones with active cameras. - Object 1 was a stand-alone camera coupled to a transmitter but not mounted on a drone. - The poor image quality in objects 2, 3, and 4 resulted from close transmitter proximity causing signal interference. - The first image comes from a video captured by the Kord Firefly narrow field-of-view camera, with the laser illuminating object 2. Applied Energetics continues to leverage its portfolio of 27 issued patents and 7 pending patents to advance next-generation defense and dual-use applications, especially fiber-based ultrashort pulse (USP) laser technologies. Learn more about Applied Energetics: https://lnkd.in/eBWivN8E Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted AERG stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of AERG or any security, and it is not intended to offer any opinion on AERG as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m

BIG DAY today in the Applied Energetics, Inc. Battle Lab! First multi-drone camera kills. Four drones, four dead cameras in four seconds through our early prototype Pulsed Laser Air Defense gimbal! #USPL #CUAS

Spartan Capital Securities, LLC and B2i Digital are pleased to announce that Grassi, a leading provider of advisory, tax, and audit services, is a Bronze Sponsor of the upcoming Spartan Capital Investor Conference on November 3rd, 2025, in New York. The Spartan Capital Investor Conference 2025 is a B2i Digital Featured Conference. See more information at https://lnkd.in/edsVSMsh. Now in its second year, the Spartan Capital Investor Conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place on November 3rd, 2025, at the Marriott Marquis Hotel in New York, this premier event will welcome more than 500 institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital. As a PCAOB-registered firm and the 52nd largest accounting firm in the nation, Grassi delivers high-quality audits with precision and expertise for public companies and those preparing for an IPO. The firm’s SEC & Capital Markets team provides hands-on guidance through IPOs, follow-on offerings, and equity and debt financing transactions. Grassi tailors post-audit recommendations to each industry, helping clients maintain compliance and position for growth. Event details and registration are available at https://lnkd.in/edsVSMsh. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Managing Director), and Julia Voss (Executive Assistant), to deliver an exceptional conference experience. Investors can register to attend: https://lnkd.in/g8Y249nF. Learn more about Grassi at https://www.grassicpas.com and https://lnkd.in/eMrjBQpQ. Follow Grassi on LinkedIn, Facebook, Instagram, and X: @grassiadvisors

United States Antimony Corporation (NYSE American, NYSE Texas: UAMY) announced the appointment of General John M. (“Jack”) Keane as an Independent Director to its board of directors, effective today, August 19, 2025. U.S. Antimony Corporation (USAC) is a B2i Digital Featured Company. The company’s comprehensive investor profile is at: https://lnkd.in/e4zC5F_v. General Keane, a four-star general with 37 years of public service, brings extensive national security and defense expertise to USAC’s board. He previously served as acting Chief of Staff and Vice Chief of Staff of the U.S. Army, directing 1.5 million soldiers and civilians in 120 countries with an annual operating budget of $110 billion. In March 2020, he was presented with the Presidential Medal of Freedom. Highlights from the company’s announcement include: • General Keane is a national security and foreign policy authority who advises presidents, cabinet officials, members of congress, international leaders, and business executives. • He currently serves as Chairman of the Institute for the Study of War and is a member of the Secretary of Defense Policy Board. • The company highlighted his extensive service and leadership background as it advances its role in critical minerals including antimony, cobalt, tungsten, and zeolite. Commenting on General Keane’s appointment to the Board of Directors, Mr. Gary C. Evans, Chairman and CEO of U.S. Antimony Corporation, stated, “We have been seeking for over a year now a former military official that would add the knowledge, strength, and experience to assist our board of directors as we continue to work more closely with various divisions of our U.S. Military. We could not be more excited to honor General Jack Keane with board membership at USAC.” To read the full news release, visit: https://lnkd.in/evNRebtF. USAC produces antimony, zeolite, and precious metals from operations in Montana, Idaho, and Mexico. Antimony products serve flame-retardant, battery, ordnance, and specialty-chemical markets, while Bear River Zeolite supports water filtration, environmental remediation, agriculture, animal nutrition, and other industrial applications. For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UAMY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UAMY or any security, and it is not intended to offer any opinion on UAMY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

OS Therapies (NYSE American: OSTX) reported second quarter 2025 financial results and provided a business update highlighting clinical and regulatory progress toward bringing the first new treatment for osteosarcoma to market in the United States in the last 40 years. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB. The company reported that the U.S. FDA confirmed OST-HER2 met the biological criteria to qualify as a Regenerative Medicine Advanced Therapy (RMAT) and issued a BLA number in preparation for a planned Accelerated Approval submission. An End of Phase 2 Meeting is scheduled for August 27, 2025, to review the Phase 2b trial in the prevention or delay of recurrence in recurrent, fully resected, pulmonary metastatic osteosarcoma. Highlights from the company’s Q2 earnings release include: • Phase 2b results: 12-month event-free survival of 35% vs 20% (p=0.0197) and updated interim 2-year overall survival of 66.6% vs 40% (p=0.0046) for OST-HER2-treated patients (n=27 for the OS readout); no grade 4 or 5 treatment-associated adverse events reported. • Commercial partnership with Eversana positions OST-HER2 for a potential U.S. launch in the first half of 2026; logistics and distribution state licensing has been initiated. • $4.2 million capital raise closed July 11, 2025, via warrant exercise inducement and exchange offering, extending cash runway into mid-2026. • The company remains eligible for a Priority Review Voucher if U.S. approval is received by September 30, 2026; recent PRV sales were $160 million (June 2025) and $155 million (May 2025). Paul Romness, MPH, Chairman & CEO of OS Therapies, stated, “The congruence between the overall survival and EFS data gives our clinical and regulatory teams confidence that we are on strong footing as we march towards our goal of receiving a Biologics Licensing Application (“BLA”) by the U.S. Food and Drug Administration (“FDA”) for OST-HER2 under the Accelerated Approval Program (“Accelerated Approval”).” Read the full release at: https://lnkd.in/eDaeM4d3. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), Jack Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on advancing its pipeline for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eaAJSfqz and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) (Nasdaq: INBS) announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Intelligent Bio Solutions is a B2i Digital Featured company. View INBS’s comprehensive profile at https://lnkd.in/gCF9hkFm. The company reported continued progress on its planned U.S. market expansion, revenue growth, and operational efficiency. Commenting on the results, Harry Simeonidis, President & CEO of Intelligent Bio Solutions, stated: “Fiscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth. We delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we’re focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world’s largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives.” Other highlights from the earnings release included: • Q4 revenue of $843,884, up 16% year-over-year and 16% quarter-over-quarter, with cartridge sales increasing 24% year-over-year. • Active customer base expanded to over 450 accounts across 24 countries, with 115 new accounts added during the fiscal year. • Advanced FDA 510(k) clearance efforts with comprehensive performance data added to submission, including human eccrine sweat testing validation. • Completed multilingual system upgrade supporting Arabic and Latin American Spanish, along with localized websites in Italian, Spanish, and Arabic. See the company’s full earnings release: https://lnkd.in/eTen6KV5. Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective fingerprint sweat-based testing worldwide. The company’s non-invasive, patented technology delivers results in under ten minutes and now supports more than 450 accounts across 24 countries in the workplace safety, law enforcement, drug treatment, and forensics markets. Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli MBus, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications.

Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. Patent and Trademark Office granted a new U.S. patent for UNI-494 to treat Chronic Kidney Disease, ensuring intellectual property protection until 2040. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f. The new patent follows the issuance of an earlier method of use patent for the treatment of Acute Kidney Injury with UNI-494. Unicycive’s investigational drug essentially works by protecting and restoring the energy-producing components of kidney cells, addressing a root cause of both acute and chronic kidney disease progression. UNI-494 has already received FDA Orphan Drug Designation for the prevention of delayed graft function (DGF) in kidney transplant patients and completed Phase I safety studies. Dr. Shalabh Gupta, MD, CEO of Unicycive, commented, “While we are focused on seeking FDA approval of our lead product oxylanthanum carbonate, we are pleased to announce the issuance of another patent for our second investigational drug, UNI-494. This patent is part of a broader intellectual property portfolio for UNI-494, which supports potential partnership opportunities and future development efforts. We have completed a Phase I clinical study in healthy volunteers and have received Orphan Drug Designation for the prevention of delayed graft function (DGF) in patients undergoing kidney transplantation.” See today’s press release at https://lnkd.in/eDQYWgpX. Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/).

The Nuvo Group kicks off an active fall conference season with strategic participation at four major industry events this September, reinforcing its engagement in the capital markets community through sponsorships and long-standing attendance. The Nuvo Group is a B2i Digital Featured Expert. Explore their profile here: https://lnkd.in/e8tSR-uq September 2025 Industry Conferences - 3-4: Gateway Conference, San Francisco, CA (Sponsor) - 3-4: ACG Great Lakes Capital Connection - Grand Rapids, MI - 8-10: Investment Company Institute ETF Conference, Nashville, TN - 16-17: National Investment Banking Association (NIBA) Annual Conference, Fort Lauderdale, FL (Sponsor) The Nuvo Group team looks forward to connecting with clients and colleagues at these events. To schedule a meeting or learn more about their comprehensive suite of services, reach out directly to Scott Lam. Led by Managing Partners Tony Barletta and Fred Jaffe, The Nuvo Group continues to serve public companies, investment banks, and law firms with accuracy, compliance expertise, and a commitment to making regulatory processes more efficient. For updates on The Nuvo Group and other Featured Experts, visit B2i Digital: https://lnkd.in/em26xtFZ.

Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI) reported Q2 2025 production averaging 3,220 BOEPD, a 3% increase year-over-year, and anticipates substantially higher production from 9 new wells coming online in H2 2025. Kolibri Global Energy Inc. is a B2i Digital Featured Company. View their complete profile at https://lnkd.in/eVHcxRGp and follow Kolibri on X, Facebook, and LinkedIn. Highlights of today’s operations update include: - Q2 2025 average production increased to 3,220 BOEPD despite 540 BOEPD reduction from wells temporarily shut-in (halted) during Lovina completion operations. - Generated Adjusted EBITDA of $7.7 million in Q2 2025. - Lovina Wells began production in late July with a 4-day average production ranging from 322 to 643 BOEPD, producing a higher oil percentage than many previous wells. - Company repurchased over 207,000 shares from April-July 2025 at an average price of $6.42/share, bringing total repurchases to 504,000+ shares since September 2024. - Production and operating expenses decreased to $7.15 per BOE in Q2 2025 vs. $8.48 per BOE in Q2 2024. In today’s news release Wolf Regener, President and CEO, commented, “We are pleased that the Company’s wells continued to perform well with average production of 3,220 boepd despite a 540 boepd reduction due to several wells that were temporarily shut-in during the quarter for the Lovina wells completion. The wells are producing a higher percentage of oil than many of our previous wells, and we are running production tubing strings this week, which could lead to higher production based on our past experience.” See the full news release at: https://lnkd.in/eddJYpxq Kolibri is led by Wolf Regener, President and CEO, alongside a seasoned technical team including CFO Gary Johnson, CPA, MBA, Director of Engineering Dan Simpson, Senior Geologist Allan Hemmy, and Landman Dalia Isaac. The company is focused on developing its oil-rich Caney acreage in Oklahoma. For additional details, please visit Kolibri’s website at: https://kolibrienergy.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted KGEI stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of KGEI or any security, and it is not intended to offer any opinion on KGEI as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.